IL188647A0 - Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) - Google Patents

Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)

Info

Publication number
IL188647A0
IL188647A0 IL188647A IL18864708A IL188647A0 IL 188647 A0 IL188647 A0 IL 188647A0 IL 188647 A IL188647 A IL 188647A IL 18864708 A IL18864708 A IL 18864708A IL 188647 A0 IL188647 A0 IL 188647A0
Authority
IL
Israel
Prior art keywords
adaptable
oral
administration system
transdermal applications
supplements
Prior art date
Application number
IL188647A
Other languages
English (en)
Original Assignee
Orina Gribova
Vol Alexander
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orina Gribova, Vol Alexander filed Critical Orina Gribova
Priority to IL188647A priority Critical patent/IL188647A0/en
Publication of IL188647A0 publication Critical patent/IL188647A0/en
Priority to EA201070827A priority patent/EA018461B1/ru
Priority to EP09700655A priority patent/EP2254590B1/en
Priority to US12/811,871 priority patent/US8936786B2/en
Priority to DK09700655.5T priority patent/DK2254590T3/da
Priority to US12/811,859 priority patent/US20100278922A1/en
Priority to CA2711556A priority patent/CA2711556A1/en
Priority to CA2711554A priority patent/CA2711554C/en
Priority to BRPI0906866-0A priority patent/BRPI0906866A2/pt
Priority to DK09701269.4T priority patent/DK2231123T3/da
Priority to AU2009203530A priority patent/AU2009203530B2/en
Priority to NZ586374A priority patent/NZ586374A/en
Priority to HK11103123.1A priority patent/HK1148945B/en
Priority to AU2009203529A priority patent/AU2009203529B2/en
Priority to PCT/IL2009/000037 priority patent/WO2009087634A2/en
Priority to ES09700655T priority patent/ES2397061T3/es
Priority to MX2010007462A priority patent/MX2010007462A/es
Priority to EP09701269A priority patent/EP2231123B1/en
Priority to PCT/IL2009/000036 priority patent/WO2009087633A2/en
Priority to JP2010541885A priority patent/JP5432183B2/ja
Priority to ES09701269T priority patent/ES2398015T3/es
Priority to KR1020107016634A priority patent/KR101588066B1/ko
Priority to ZA2010/04480A priority patent/ZA201004480B/en
Priority to IL206835A priority patent/IL206835A/en
Priority to IL206834A priority patent/IL206834A/en
Priority to US14/565,416 priority patent/US9949924B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL188647A 2008-01-08 2008-01-08 Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) IL188647A0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
IL188647A IL188647A0 (en) 2008-01-08 2008-01-08 Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
KR1020107016634A KR101588066B1 (ko) 2008-01-08 2009-01-08 단백질 및 펩티드 치료제의 경구 투여 방법 및 조성물
HK11103123.1A HK1148945B (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of protein and peptide therapeutic agents
PCT/IL2009/000037 WO2009087634A2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of insulin
US12/811,871 US8936786B2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of protein and peptide therapeutic agents
DK09700655.5T DK2254590T3 (da) 2008-01-08 2009-01-08 Fremgangsmåder og præparater til oral administration af insulin
US12/811,859 US20100278922A1 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of insulin
CA2711556A CA2711556A1 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of insulin
CA2711554A CA2711554C (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of protein and peptide therapeutic agents
BRPI0906866-0A BRPI0906866A2 (pt) 2008-01-08 2009-01-08 métodos e composições para administração oral de agentes terapêutico de proteína e peptídeo
DK09701269.4T DK2231123T3 (da) 2008-01-08 2009-01-08 Fremgangsmåder og præparater til oral administrationaf protein- og peptidterapimidler
AU2009203530A AU2009203530B2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of insulin
NZ586374A NZ586374A (en) 2008-01-08 2009-01-08 Compositions comprising an oil, a polysaccharide in intimate association with silica nanoparticles and a protein or peptide non-covalently associated with said nanoparticles and polysaccharide
EA201070827A EA018461B1 (ru) 2008-01-08 2009-01-08 Способы и композиции для перорального введения белковых и пептидных терапевтических средств
AU2009203529A AU2009203529B2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of protein and peptide therapeutic agents
EP09700655A EP2254590B1 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of insulin
ES09700655T ES2397061T3 (es) 2008-01-08 2009-01-08 Procedimientos y composiciones para la administración oral de insulina
MX2010007462A MX2010007462A (es) 2008-01-08 2009-01-08 Metodos y composiciones para administracion oral de agentes terapeuticos de peptidos y proteinas.
EP09701269A EP2231123B1 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of protein and peptide therapeutic agents
PCT/IL2009/000036 WO2009087633A2 (en) 2008-01-08 2009-01-08 Methods and compositions for oral administration of protein and peptide therapeutic agents
JP2010541885A JP5432183B2 (ja) 2008-01-08 2009-01-08 タンパク質およびペプチドの治療薬の経口投与に関する方法および組成物
ES09701269T ES2398015T3 (es) 2008-01-08 2009-01-08 Métodos y composiciones para la administración oral de agentes terapéuticos de péptidos y proteínas
ZA2010/04480A ZA201004480B (en) 2008-01-08 2010-06-24 Methods and compositions for oral administration of protein and peptide therapeutic agents
IL206835A IL206835A (en) 2008-01-08 2010-07-06 Pharmaceutical compositions containing oil and particulates for oral administration of insulin and methods for their preparation
IL206834A IL206834A (en) 2008-01-08 2010-07-06 Pharmaceutical compositions containing oil and particulate matter for the oral administration of proteins and peptides with medical activity
US14/565,416 US9949924B2 (en) 2008-01-08 2014-12-09 Methods and compositions for oral administration of protein and peptide therapeutic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL188647A IL188647A0 (en) 2008-01-08 2008-01-08 Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)

Publications (1)

Publication Number Publication Date
IL188647A0 true IL188647A0 (en) 2008-11-03

Family

ID=40326402

Family Applications (3)

Application Number Title Priority Date Filing Date
IL188647A IL188647A0 (en) 2008-01-08 2008-01-08 Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
IL206835A IL206835A (en) 2008-01-08 2010-07-06 Pharmaceutical compositions containing oil and particulates for oral administration of insulin and methods for their preparation
IL206834A IL206834A (en) 2008-01-08 2010-07-06 Pharmaceutical compositions containing oil and particulate matter for the oral administration of proteins and peptides with medical activity

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL206835A IL206835A (en) 2008-01-08 2010-07-06 Pharmaceutical compositions containing oil and particulates for oral administration of insulin and methods for their preparation
IL206834A IL206834A (en) 2008-01-08 2010-07-06 Pharmaceutical compositions containing oil and particulate matter for the oral administration of proteins and peptides with medical activity

Country Status (15)

Country Link
US (3) US8936786B2 (https=)
EP (2) EP2231123B1 (https=)
JP (1) JP5432183B2 (https=)
KR (1) KR101588066B1 (https=)
AU (2) AU2009203530B2 (https=)
BR (1) BRPI0906866A2 (https=)
CA (2) CA2711554C (https=)
DK (2) DK2231123T3 (https=)
EA (1) EA018461B1 (https=)
ES (2) ES2398015T3 (https=)
IL (3) IL188647A0 (https=)
MX (1) MX2010007462A (https=)
NZ (1) NZ586374A (https=)
WO (2) WO2009087633A2 (https=)
ZA (1) ZA201004480B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2521295Y2 (ja) 1991-11-13 1996-12-25 シーケーディ株式会社 流体混合器
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
CA2767342C (en) * 2009-07-09 2018-05-01 Oshadi Drug Administration Ltd. Matrix carrier compositions, methods and uses
DK3311834T3 (da) * 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
US20140057856A1 (en) * 2012-08-22 2014-02-27 The Regents Of The Universtiy Of California Compositions and Methods For Enhancing Sialic Acid Levels In Tissue
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
AU2014210751A1 (en) * 2013-01-29 2015-08-06 Oshadi Drug Administration Ltd. Pharmaceutical compositions for oral treatment of diabetes
ES2502691B1 (es) * 2013-09-25 2015-07-07 Sani-Red, S.L. Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos
US9474720B2 (en) 2013-11-04 2016-10-25 BioPharmX, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
US9168211B2 (en) * 2014-03-28 2015-10-27 Johnson & Johnson Consumer Inc. Method of making an anhydrous, pigmented composition
KR102418550B1 (ko) * 2015-11-03 2022-07-06 삼성전자주식회사 포토 레지스트 패턴 형성 방법 및 이를 이용한 반도체 장치 제조 방법
US10660941B2 (en) 2016-02-19 2020-05-26 Indian Institute Of Technology, Bombay Orally administrable pharmaceutical preparation containing protein
RU2718554C1 (ru) * 2017-09-25 2020-04-08 Георгий Георгиевич Чумбуридзе Термостабильная композиция, обладающая антивирусной и антибактериальной активностью и ее использование
IT201800007947A1 (it) * 2018-08-07 2020-02-07 Vetagro Int Srl Metodo per preparare una composizione di aminoacidi per consentire la corrispondenza dei singoli fabbisogni di amminoacidi ad un soggetto in base all'età, al genere, all'attività fisica e alla genetica
BR112021018817A2 (pt) * 2019-04-11 2021-11-23 Scherer Technologies Llc R P Formulação para suprimento oral de proteínas, peptídeos e moléculas pequenas com pouca permeabilidade
US20220296683A1 (en) * 2019-09-20 2022-09-22 University College Dublin Oral delivery system
EP3937983B1 (en) 2019-12-17 2025-02-05 9286-3620 Québec Inc. Oral delivery systems based on in situ forming protein/polysaccharide coacervates
KR20220132598A (ko) 2020-01-28 2022-09-30 제넨테크, 인크. 암 치료를 위한 IL15/IL15R 알파 이종이량체 Fc-융합 단백질
EP4181912A1 (en) 2020-07-15 2023-05-24 Schabar Research Associates LLC Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US20240315972A1 (en) 2021-07-12 2024-09-26 Zidkiyahu Simenhaus Protein containing bio-active compositions comprising cellulose microparticle carriers
EP4536684A1 (en) 2022-06-13 2025-04-16 B.A.I. Laboratories, LLC Interleukin-13 binding cyclic oligopeptides and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3252859A (en) * 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
ES2027518A6 (es) 1990-12-18 1992-06-01 Andromaco Lab Procedimiento para la preparacion de nuevas asociaciones no covalentes polisacarido-proteina con actividad farmacologica.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5260002A (en) * 1991-12-23 1993-11-09 Vanderbilt University Method and apparatus for producing uniform polymeric spheres
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US20040018236A1 (en) 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
ES2093562B1 (es) * 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6322765B1 (en) 1996-02-15 2001-11-27 Wacker-Chemie Gmbh Process for preparing silicon dioxide
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
FR2767718B1 (fr) * 1997-08-28 1999-10-22 Oreal Emulsion eau-dans-huile comprenant de la silice pyrogenee et un alkylether de polysaccharide
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
PL333331A1 (en) * 1997-09-09 1999-12-06 Select Release Coated particles, method of producing them and their application
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
ES2255490T3 (es) 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
DE10001172A1 (de) * 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
JP4631119B2 (ja) * 2000-01-28 2011-02-16 Ｊｓｒ株式会社 疎水化コロイダルシリカの製造方法
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6548264B1 (en) * 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
JP2004521857A (ja) * 2000-06-29 2004-07-22 エミスフェアー・テクノロジーズ・インク 活性剤の送達のための化合物及び組成物
DE50012404D1 (de) 2000-08-11 2006-05-11 Lohmann Animal Health Gmbh W/o Emulsion Adjuvanszuzammensetzungen für Impstoffen
WO2002032398A2 (en) 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for drug delivery
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
US6698247B2 (en) * 2001-05-04 2004-03-02 Corning Incorporated Method and feedstock for making silica by flame combustion
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1458361A4 (en) * 2001-11-20 2007-04-25 Advanced Inhalation Res Inc COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20060177495A1 (en) * 2001-12-21 2006-08-10 Christine Allen Polymer-lipid delivery vehicles
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
AU2003210477A1 (en) 2002-01-09 2003-07-30 Enzrel, Inc. Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds
EP1472351B1 (en) 2002-02-07 2007-06-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
US7244498B2 (en) * 2002-06-12 2007-07-17 Tda Research, Inc. Nanoparticles modified with multiple organic acids
US7090868B2 (en) * 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
CA2511530C (en) 2003-01-06 2013-07-09 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20040242729A1 (en) 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
JP2007523050A (ja) 2003-09-17 2007-08-16 カイアズマ・リミテッド 生物学的障壁を通した透過を容易にすることのできる組成物
US20050170004A1 (en) * 2003-10-31 2005-08-04 Vered Rosenberger Nanoparticles for drug delivery
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US8241670B2 (en) 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
US7288134B2 (en) 2004-09-10 2007-10-30 International Business Machines Corporation Dumbbell-like nanoparticles and a process of forming the same
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
WO2006062506A1 (en) 2004-12-03 2006-06-15 Enzrel, Inc. Chitosan-coated liposome drug delivery of antioxidant or anti-inflammatory compounds
WO2007017700A1 (en) * 2005-08-09 2007-02-15 University Of Sunderland Hydrophobic silica particles and methods of making same
ES2761937T3 (es) 2005-10-24 2020-05-21 Magsense Life Sciences Inc Método para preparar micropartículas recubiertas con polímero
WO2007056424A2 (en) * 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Controlled-release emulsion compositions
US20070258889A1 (en) * 2005-11-09 2007-11-08 Montana State University Novel nanoparticles and use thereof
WO2008048298A2 (en) 2005-11-21 2008-04-24 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
CA2767342C (en) * 2009-07-09 2018-05-01 Oshadi Drug Administration Ltd. Matrix carrier compositions, methods and uses

Also Published As

Publication number Publication date
US9949924B2 (en) 2018-04-24
EP2254590B1 (en) 2012-10-10
WO2009087634A2 (en) 2009-07-16
KR20100119541A (ko) 2010-11-09
EP2231123A2 (en) 2010-09-29
IL206835A0 (en) 2010-12-30
EA201070827A1 (ru) 2010-12-30
EP2254590A4 (en) 2012-01-25
EP2231123B1 (en) 2012-10-24
DK2254590T3 (da) 2013-01-28
ES2398015T3 (es) 2013-03-13
MX2010007462A (es) 2010-08-23
CA2711556A1 (en) 2009-07-16
WO2009087633A2 (en) 2009-07-16
CA2711554A1 (en) 2009-07-16
AU2009203530A1 (en) 2009-07-16
IL206835A (en) 2017-09-28
IL206834A (en) 2015-09-24
AU2009203529A1 (en) 2009-07-16
DK2231123T3 (da) 2013-02-04
US8936786B2 (en) 2015-01-20
WO2009087634A3 (en) 2010-01-07
EP2254590A2 (en) 2010-12-01
AU2009203530B2 (en) 2013-10-24
US20150147399A1 (en) 2015-05-28
EA018461B1 (ru) 2013-08-30
US20100297245A1 (en) 2010-11-25
JP5432183B2 (ja) 2014-03-05
AU2009203529B2 (en) 2013-09-05
KR101588066B1 (ko) 2016-01-22
EP2231123A4 (en) 2011-09-07
US20100278922A1 (en) 2010-11-04
WO2009087633A3 (en) 2010-03-11
BRPI0906866A2 (pt) 2019-02-26
IL206834A0 (en) 2010-12-30
ES2397061T3 (es) 2013-03-04
HK1148945A1 (en) 2011-09-23
NZ586374A (en) 2011-10-28
ZA201004480B (en) 2011-09-28
CA2711554C (en) 2017-01-03
JP2011509287A (ja) 2011-03-24

Similar Documents

Publication Publication Date Title
IL188647A0 (en) Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
IL275854A (en) Pharmaceutical composition and its administration
EP2213318A4 (en) DRUG SOLUTION DELIVERY SYSTEM AND DRUG SOLUTION ADMINISTRATION CANNULA
ZA201003435B (en) Secure medication transport and administration system
PL2379132T3 (pl) Układ i sposób infuzji leku
IL207512A0 (en) Pharmaceutical composition for poorly soluble drugs
EP2299989A4 (en) STERILIZED TRANSDERMAL DRUG DELIVERY SYSTEM
EP2329810A4 (en) DRUG DISPENSING SYSTEM WITH MAGNETIC RETENTION, MANUFACTURING PROCESS AND APPLICATION
ZA200900423B (en) Methods and medicaments for administration of ibuprofen
EP1980271A4 (en) MEDICINE FOR TRANSNASAL ADMINISTRATION
SI3581223T1 (sl) Sistemi za samodejno dajanje zdravila
IL200551A0 (en) Solid pharmaceutical and vaccine dose
ZA201100615B (en) Appetising medicament for oral administration in solid form
ZA201006557B (en) Drug delivery systems comprising weakly basic drugs and organic acids
IL217500A0 (en) Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them
EP2155175A4 (en) MATRIX-TYPE TRANSDERMAL ACTIVE COMPOSITION SYSTEM AND MANUFACTURING METHOD THEREFOR
PL2394648T3 (pl) Kompozycja farmaceutyczna do podawania doustnego
EP2263637A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
ZA200902061B (en) Packaging system for pharmaceutical compositions and kit for intravenous administration
EP2206519A4 (en) MEDICINAL PREPARATION FOR ORAL ADMINISTRATION
ZA201006517B (en) Estradiol-containing drug delivery system
HU0900482D0 (en) Pharmaceutical formulation for oral administration
ZA201102405B (en) Pharmaceutical composition for oral administration
EP2529755A4 (en) PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION
ZA200904563B (en) Transdermal Therapeutic system for administering water-soluble active ingredients